Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

Author:

Muchtar Eli1,Wisniowski Brendan2,Geyer Susan3,Palladini Giovanni45,Milani Paolo45,Merlini Giampaolo45,Schönland Stefan6,Veelken Kaya6,Hegenbart Ute6,Leung Nelson1,Dispenzieri Angela1,Kumar Shaji K.1,Kastritis Efstathios7,Dimopoulos Meletios A.7,Liedtke Michaela8,Ulloa Patricia8,Sanchorawala Vaishali9,Szalat Raphael9,Dooley Katharine3,Landau Heather10,Petrlik Erica10,Lentzsch Suzanne11,Coltoff Alexander11,Bladé Joan12,Cibeira M. Teresa12,Cohen Oliver2,Foard Darren2,Gillmore Jullian2,Lachmann Helen2,Wechalekar Ashutosh2,Gertz Morie A.1

Affiliation:

1. Division of Hematology, Mayo Clinic, Rochester, Minnesota

2. National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, England

3. Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota

4. Department of Molecular Medicine, University of Pavia, Pavia, Italy

5. Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and Department of Molecular Medicine, University of Pavia, Pavia, Italy

6. Medical Department V, Amyloidosis Center, University of Heidelberg, Germany

7. Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

8. Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California

9. Section of Hematology and Oncology, Amyloidosis Center, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts

10. Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York

11. Division of Hematology/Oncology, Columbia University Medical Center, New York, New York

12. Department of Hematology, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clinic, Barcelona, Spain

Abstract

ImportanceKidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes.ObjectiveTo validate graded kidney response criteria and their association with kidney and overall survival (OS).Design, Setting, and ParticipantsThis retrospective, multicenter cohort was conducted at 10 referral centers for amyloidosis from 2010 to 2015 and included patients with kidney AL amyloidosis that was evaluable for kidney response and who achieved at least hematologic partial response within 12 months of diagnosis. The median follow-up was 69 (54-88) months. Data analysis was conducted in 2023.ExposureFour kidney response categories based on the reduction in pretreatment 24-hour urine protein (24-hour UP) levels: complete response (kidCR, 24-hour UP ≤200 mg), very good partial response (kidVGPR, >60% reduction in 24-hour UP), partial response (kidPR, 31%-60% reduction), and no response (kidNR, ≤30% reduction). Kidney response was assessed at landmark points (6, 12, and 24 months) and best kidney response.Main Outcomes and MeasuresCumulative incidence of progression to KRT and OS.ResultsSeven-hundred and thirty-two patients (335 women [45.8%]) were included, with a median (IQR) age of 63 (55-69) years. The median (IQR) baseline 24-hour proteinuria and estimated glomerular filtration rate was 5.3 (2.8-8.5) g per 24 hours and 72 (48-92) mL/min/1.73m2, respectively. In a competing-risk analysis, the 5-year cumulative incidence rates of progression to KRT decreased with deeper kidney responses as early as 6 months from therapy initiation (11%, 12%, 2.1%, and 0% for kidNR, kidPR, kidVGPR, and kidCR, respectively; P = .002) and were maintained at 12 months and 24 months and best kidney response. Patients able to achieve kidCR/kidVGPR by 24 months and at best response had significantly better OS compared with kidPR/kidNR. Kidney progression, defined as a 25% or greater decrease in estimated glomerular filtration rate, was associated with cumulative incidence of progression to KRT and OS.Conclusions and RelevanceThe results of this cohort study suggest that graded kidney response criteria offers clinically and prognostically meaningful information for treating patients with kidney AL amyloidosis. The response criteria potentially inform kidney survival based on the depth of reduction in 24-hour proteinuria levels and demonstrate an OS advantage for those able to achieve kidCR/kidVGPR compared with kidPR/kidNR. Taken together, achievement of at least kidVGPR by 12 months is needed to ultimately improve kidney and patient survival.

Publisher

American Medical Association (AMA)

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3